175 related articles for article (PubMed ID: 38087810)
1. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract][Full Text] [Related]
2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
3. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
[TBL] [Abstract][Full Text] [Related]
6. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
Hadfield MJ; Sullivan RJ
Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
[TBL] [Abstract][Full Text] [Related]
7. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G; Neyns B
Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
[TBL] [Abstract][Full Text] [Related]
8. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases.
Fujisawa Y; Ito T; Kato H; Irie H; Kaji T; Maekawa T; Asai J; Yamamoto Y; Fujimura T; Nakai Y; Yasuda M; Matsuyama K; Muto I; Matsushita S; Uchi H; Nakamura Y; Uehara J; Yoshino K
Eur J Cancer; 2021 Mar; 145():210-220. PubMed ID: 33503528
[TBL] [Abstract][Full Text] [Related]
9. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
10. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.
Kim DY; Swetter SM; Huhmann L; Dizon MP; Ferguson JM; Osborne TF; Spence AC; Ziad A; Fillmore N; Hartman RI
J Am Acad Dermatol; 2024 Mar; 90(3):620-623. PubMed ID: 37924953
[No Abstract] [Full Text] [Related]
12. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
13. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
[TBL] [Abstract][Full Text] [Related]
14. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A; Daud AI
Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
[TBL] [Abstract][Full Text] [Related]
19. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]